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Abstract: Assessment of the immune response to tumors is growing
in importance as the prognostic implications of this response are
increasingly recognized, and as immunotherapies are evaluated and
implemented in diﬀerent tumor types. However, many diﬀerent
approaches can be used to assess and describe the immune
response, which limits eﬀorts at implementation as a routine clin-
ical biomarker. In part 1 of this review, we have proposed a
standardized methodology to assess tumor-inﬁltrating lymphocytes
(TILs) in solid tumors, based on the International Immuno-
Oncology Biomarkers Working Group guidelines for invasive
breast carcinoma. In part 2 of this review, we discuss the available
evidence for the prognostic and predictive value of TILs in com-
mon solid tumors, including carcinomas of the lung, gastro-
intestinal tract, genitourinary system, gynecologic system, and head
and neck, as well as primary brain tumors, mesothelioma and
melanoma. The particularities and diﬀerent emphases in TIL
assessment in diﬀerent tumor types are discussed. The standardized
methodology we propose can be adapted to diﬀerent tumor types
and may be used as a standard against which other approaches can
be compared. Standardization of TIL assessment will help clini-
cians, researchers and pathologists to conclusively evaluate the
utility of this simple biomarker in the current era of
immunotherapy.
Key Words: lymphocytes, tumor-inﬁltrating, biomarkers, cancer,
immunotherapy, pathology
(Adv Anat Pathol 2017;00:000–000)
Assessment of tumor-inﬁltrating lymphocytes (TILs) isgrowing in importance as evidence emerges of the prog-
nostic and potentially predictive signiﬁcance of TILs in many
diﬀerent tumor types, and as immunotherapies show exciting
results in clinical trials and clinical practice. A signiﬁcant
research eﬀort is underway to identify reliable biomarkers to
select patients with the highest likelihood of responding to
immunotherapeutic agents. As discussed in part 1 of this
review, TIL assessment on hematoxylin and eosin (H&E)
sections has shown clinical validity as a prognostic marker in
invasive breast carcinoma,1 and is reproducible,2 aﬀordable
and widely available. However, many diﬀerent approaches
are used to assess the immune inﬁltrate in tumors with highly
variable requirements, costs and complexity. In part 1 of this
review, we proposed a standardized methodology for TIL
assessment in solid tumors, based on the International
Immuno-Oncology Biomarkers Working Group guidelines
for TIL assessment in invasive breast carcinoma.1 In part 2,
we discuss the TILs literature in diﬀerent tumor types, and
suggest ways in which the proposed methodology may be
applied to these tumor types and adapted as required based
on the available evidence and expert opinion.
TILs IN MELANOMA
Reporting of TILs in primary cutaneous melanoma
has long been routine in histopathology practice, following
the early recognition of their prognostic signiﬁcance.3–5 The
host immune response to melanoma has been highlighted
by the recent impressive results of immune checkpoint
inhibitor therapy, which is now standard of care in meta-
static melanoma.6 The immune inﬁltrate in melanomas is
therefore of great interest to clinicians and researchers, both
as a prognostic marker and as a potential predictive marker
of response to immunotherapy. TILs in melanoma have
been well studied, and the current body of literature is
discussed below with regard to scoring methodologies,
prognostic value, predictive value of sentinel node pos-
itivity, and scoring in metastatic deposits.
The prognostic value of TILs in primary cutaneous
melanoma has been debated in the literature over the past
few decades. Initial reports established simple H&E-based
scoring criteria,4,5 classifying the immune inﬁltrate as brisk
(TILs present throughout the substance of the vertical
growth phase or present and inﬁltrating across the entire
base of the vertical growth phase), nonbrisk (TILs noted in
one or more foci of the vertical growth phase) or absent
(entirely absent from the tumor or present but not inﬁl-
trating the melanoma cell nests). The immune inﬁltrate as
classiﬁed by this system was found to be an independent
prognostic factor, with an adjusted odds ratio for survival
of 11.3 for a brisk inﬁltrate and 3.5 for a nonbrisk inﬁl-
trate.5 This study established strict guidelines to deﬁne a
“TIL”—the lymphocytes must inﬁltrate and disrupt the
tumor cell nests, that is, stromal lymphocytes are not
included in the assessment.5 Clark’s TIL scoring system is
reproducible among pathologists7 and has subsequently
been validated in studies involving over 5000 patients,8–11
all reporting that TILs are an independent prognostic fac-
tor in multivariate analyses. In 2012, a group at the
Melanoma Institute of Australia proposed a modiﬁcation
to the system described by Clark and colleagues, intro-
ducing a grade based on the density (absent/mild/moderate/
marked, score 0 to 3) and distribution (absent/focal/multi-
focal/diﬀuse, score 0 to 3) of the immune inﬁltrate.12 The
possible combinations were collapsed into 4 TILs grades as
follows: grade 0=absent; grade 1=mild or moderate
focal inﬁltrate, or mild multifocal inﬁltrate; grade
2=marked focal, moderate or marked multifocal, or mild
diﬀuse inﬁltrate; grade 3=moderate or marked diﬀuse
inﬁltrate.12 In a cohort of 1865 melanomas over 0.75mm
thick, this scheme was an independent predictor of mela-
noma speciﬁc survival, with a 5-year survival of 100% seen
in the patients with grade 3 TILs,12 however it remains to
be validated in an independent cohort.
Despite this body of evidence, a number of studies
have also been published that report a lack of independent
prognostic value using Clark’s scoring system.13–15 Rao
et al16 found that the diﬀerence in overall survival across
the 3 TILs groups was not statistically signiﬁcant but a
signiﬁcant diﬀerence was observed when the absent TILs
group was compared with those with TILs present, brisk or
nonbrisk. In a recent population-based study of over 4000
patients,17 Eriksson and colleagues used a TIL scoring
system of absent-to-sparse/moderate/marked based on
H&E assessment, which was approximated to the absent/
nonbrisk/brisk system described by Clark et al.5 This TILs
score was not found to be an independent prognostic
factor.17
The discrepant results from these studies may be in
part due to diﬀering patient populations, in particular,
diﬀerences in melanoma thickness and growth phase.
Studies including a large proportion of thin melanomas in
which only the radial growth phase is present appear more
likely to report an absence of an association between TILs
and survival,15,17 however a signiﬁcant association was
found in the study by Thomas et al9 in which 82% of cases
were <1.0mm thick. A meta-analysis of high quality
published studies may be of value to resolve the issue.
Fortunately, as many of these studies have used a standard
TILs scoring method, combination in a meta-analysis
should have validity.
Studies using immunohistochemistry (IHC) to delin-
eate and quantify TIL subsets help to demonstrate the
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importance of the host immune response in melanoma.
CD69+ activated lymphocytes,18 CD20+ B cells,19 and
cytotoxic T cells identiﬁed by granzyme B20 have been
shown to correlate with improved survival. In contrast,
FOXP3+ Tregs negatively impacted survival.
21 Multi-
spectral IHC can be used reliably even in the presence of
heavy melanin pigmentation22 and has been used to predict
the yield of TILs generated for adoptive cell transfer.23
Importantly, Weiss et al11 found no added prognostic
beneﬁt to quantifying lymphocyte subsets by IHC over a
3-tiered H&E assessment.
Although the therapeutic beneﬁt of sentinel lymph
node biopsy in melanoma is still being debated,24 it is well
established as an important prognostic factor.25 Recent
studies have shown that the TIL score in the primary tumor
is inversely correlated with sentinel node involve-
ment.12,14,15,26,27 This has been demonstrated both with the
scoring system described by Clark et al14,15,27 and the
modiﬁed Melanoma Institute of Australia system.12 Wong
et al28 examined a cohort of patients with thin melanomas
(<1mm) who underwent sentinel lymph node biopsy and
found no association between TILs and sentinel lymph
node positivity, however numbers were small and did not
represent the usual patient population undergoing sentinel
lymph node biopsy. Interestingly, although ﬁnding a sig-
niﬁcant association between TILs and sentinel lymph node
positivity, and between sentinel lymph node positivity and
survival, 2 studies did not ﬁnd TILs to be an independent
prognostic factor for survival.14,15
While most research in other solid tumors has focused
on the primary lesion, evaluation of TILs in metastatic sites
has also been the focus of investigation in melanoma. In
1996, Mihm et al29 showed that the TILs scoring method of
Clark and colleagues could be slightly modiﬁed and applied
to metastatic tumor deposits in regional nodes, likening the
expansive proliferation of malignant cells to the vertical
growth phase of the primary tumor. The lymphocytic
inﬁltrate within the metastatic tumor nests (carefully
excluding the surrounding lymphoid stroma from the
assessment) was found to be an independent prognostic
factor.29 Similar results were demonstrated by Bogunovic
et al30 and Kakavand et al,31 using both H&E TIL assess-
ment and semiquantitative scoring of immunohistochemical
stained sections. Recently, as part of The Cancer Genome
Atlas project, a modiﬁed TILs scoring system was used to
correlate histological assessment of TILs with RNA-based
gene expression proﬁling and survival.32 The majority of
samples submitted for this study were from metastatic
sites.32 This system scored lymphocyte density (score 0 to 3)
and distribution (score 0 to 3) score to produce a 7-tiered
L-score, which was found to be signiﬁcantly associated with
the “immune” subclass of melanomas identiﬁed to be
rich in immune-related transcripts on mRNA expression
proﬁling.32 Although more information is potentially pro-
vided by this more detailed scoring system, it remains to be
validated in an independent cohort and compared with the
traditional 3-tiered system of Clark et al.5
Assessing TILs in metastatic deposits within lymph
nodes is clearly complicated by the presence of preexisting
lymphoid stroma. As per the guidelines established by
Clark et al5 and Mihm et al,29 only lymphocytes in direct
contact with melanoma cells and disrupting melanoma cell
nests should be included in the assessment. As this recom-
mendation is the same for the primary lesion, little mod-
iﬁcation is required to adapt the scoring system to the
metastatic setting. As discussed further in part 1 of this
review, how to assess TILs in metastases, particularly
lymph nodes, is less clear for other tumor types. For
example, as the guidelines for TILs assessment in invasive
breast cancer recommend only assessing the stromal com-
partment,1 modiﬁcation of the protocol will be required to
investigate the impact of TILs in lymph node metastases.
For further discussion of TIL assessment in metastatic
deposits, including those in lymph nodes, the reader is
referred to part 1 of this review.
Further investigation of the potential prognostic
importance of stromal TILs in melanoma would be of
interest. The tumor stroma, that is, the stroma within the
borders of the invasive tumor, between the tumor nests, is
altered relative to the adjacent stroma and has important
interactions with the tumor cells.33,34 We consider this
stroma to be an integral part of the tumor, and hence
stromal TILs should also be assessed as they may also play
an important role in melanoma. Following Clark et al’s5
initial deﬁnition of TILs, lymphocytes within the stromal
compartment have been largely excluded from analysis in
melanoma.
Another area of interest is the potential importance of
peritumoral lymphocytes. Less is known about the potential
prognostic eﬀect of a marked lymphocytic inﬁltrate in this
compartment. Ladanyi et al35–37 have considered peritu-
moral and intratumoral lymphocytes separately in a series
of small immunohistochemical studies, and have found that
high numbers of peritumoral activated T helper cells, B cells,
and mature dendritic cells are associated with improved
survival. In contrast, Hillen et al18 found no signiﬁcant
association between survival and the density of peritumoral
lymphocytes subsets deﬁned by IHC. A recent study
attracting much interest showed that the CD8+ T cell
density at the invasive margin of melanoma metastases was
able to consistently predict response to immune checkpoint
inhibitor therapy with pembrolizumab, performing better
than CD8+ T cell density within the tumor and better than
CD4+, PD-1+, and PD-L1+ cell densities within tumor
or at the invasive margin.38 The invasive margin was deﬁned
as an area outside the tumor nests, which were delineated by
S100 IHC.38 This important study has renewed interest in
the potential importance of peritumoral lymphocytes, given
the ongoing search for a reliable biomarker able to predict
response to immune checkpoint inhibitor therapy.
As there is signiﬁcant prognostic information available
from examining both stromal TILs and intratumoral TILs
in other tumor types, it would be of interest to further
examine the stromal compartment as well as the peritu-
moral area in melanoma. As such, standardized deﬁnitions
of these compartments would be of value to pathologists
and researchers, as illustrated in part 1 of this review.
The deﬁnition of “invasive margin” used by Galon and
colleagues39 is preferred, and we suggest this will be appli-
cable to most solid tumor types as well as colorectal car-
cinoma. This deﬁnes the invasive margin as the region
centered on the border separating the host tissue from the
malignant nests, with an extent of 1mm.39 Tissue within
this region is considered central tumor and beyond this
region is considered peritumor. While lacking speciﬁc sup-
porting evidence, this is a pragmatic, easily applied and
widely applicable deﬁnition. In invasive breast carcinoma,
there is currently no evidence to suggest a functional dif-
ference between lymphocytes at the invasive margin and
within the central tumor stroma, and it is recommended
Hendry et al Adv Anat Pathol  Volume 00, Number 00, ’’ 2017
4 | www.anatomicpathology.com Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
Copyright r 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
that these areas are combined in daily practice.1 However,
in melanoma, colorectal carcinoma (discussed below) and
potentially other tumor types, there does appear to be value
in separating the 2 areas, at least in the research setting.
With clear deﬁnitions such as these in place, it is hoped
that data from future studies can be combined and com-
pared in a valid manner. A suggested approach to applying
the proposed standardized methodology to TIL assessment
in melanoma is illustrated in Figure 1 and detailed further
in a tutorial available online in Supplementary File 1,
Supplemental Digital Content 1 (http://links.lww.com/
PAP/A17).
TILs IN COLORECTAL CARCINOMA
Recognition of the prognostic impact of TILs in color-
ectal carcinoma dates back to the 1930s.40 Much evidence has
accumulated in the intervening years, such that proposals
have been made to include an assessment of the immune
inﬁltrate in the traditional TNM staging system.41 Early
interest in colorectal cancer TILs revolved around their
association with cancers showing sporadic or familial micro-
satellite instability (MSI). In recent years, attention has shifted
to the prognostic value of TILs assessment, diﬀerent scoring
methodologies and the ability of TILs scoring to predict
response to neoadjuvant therapy in rectal cancer.
Colorectal adenocarcinoma arises through genetically
distinct pathways—the traditional stepwise adenoma-
carcinoma sequence characterized by mutations in APC,
TP53, and KRAS and chromosomal instability, the CpG
island methylator phenotype in which high levels of promoter
methylation lead to silencing of tumor suppressor genes, and
the MSI pathway characterized by deﬁcient DNA mismatch
repair (dMMR).42,43 dMMR/MSI-high cancers often have a
distinctive morphology, and these histologic features including
TILs, Crohn-like lymphocytic reaction, mucinous/signet-ring
cell diﬀerentiation and medullary growth pattern form part of
the 2004 revised Bethesda criteria to select patients for further
MSI testing.44 Many studies have shown the value of a his-
tologic assessment of TILs in predicting MSI status, alone or
as part of a predictive model.45–49 A count of intraepithelial
lymphocytes on H&E alone can predict MSI status with a
sensitivity of 21% to 93% and a speciﬁcity of 62% to 97%,
with cutoﬀs ranging from 2 to 5 intraepithelial lymphocytes
per high power ﬁeld.45–48 Joost et al49 compared 5
diﬀerent predictive models incorporating an assessment of
TILs,46,48,50–52 with sensitivities ranging from 78% to 97%
and speciﬁcities of 46% to 93%. However, National Com-
prehensive Cancer guidelines now recommend universal
screening of all colorectal carcinomas for MMR/MSI status
to identify Lynch syndrome,53 and the prognostic strat-
iﬁcation of all patients based on MMR/MSI status is
increasingly being recommended.54–56 Universal screening has
become routine practice in many histopathology laboratories,
with a panel of 2 or 4 immunohistochemical stains reliably
identifying dMMR colorectal carcinomas.57,58 As such, the
imperfect sensitivity and speciﬁcity of TILs and other histo-
logic features is no longer considered suﬃcient to identify
these cases in practice. It has recently been recognized that,
although rare, POLE proofreading domain mutations are
present in a small subset of colorectal carcinomas, and result
in an ultramutated, highly immunogenic phenotype with
improved prognosis.59 As is discussed further below in the
“Endometrial carcinoma,” section the high level of TILs in
these tumors may prove to have diagnostic and therapeutic
importance.
In addition to identifying dMMR/MSI-high colorectal
carcinomas, TILs have also been shown to have important
prognostic value in all colorectal carcinomas, regardless of
MSI status.60 Both semiquantitative H&E-based scoring
and digital quantitation of TILs on IHC have received
much attention in the literature. In 1986, Jass61 published a
semiquantitative H&E assessment of TILs in rectal cancer
which was found to be an independent prognostic factor.
The lymphocytic inﬁltrate was described as predominating
in the “delicate connective tissue lamina at the growing
tissue margin,” that is, in the stromal compartment, and
scored as little/none, moderate or pronounced.61 Semi-
quantitative H&E assessment also formed the basis of the
Klintrup-Ma¨kinen score developed in 2005, where the
immune inﬁltrate was scored from 0 to 3, with score 0=no
increase in inﬂammatory cells; score 1=a patchy increase
of inﬂammatory cells at the invasive margin, but no
destruction of invading cancer cell islets; score 2=a band-
like inﬁltrate at the invasive margin with some destruction
of cancer cell islets; and score 3=a very prominent
inﬂammatory reaction, forming a cup-like zone at the
invasive margin, and frequent and invariable destruction of
cancer cell islets.62 While again focusing on the invasive
margin, the importance of intratumoral TILs disrupting
cancer cell nests is also emphasized. Scores were collapsed
into low-grade inﬂammation (score 0 to 1) and high-grade
inﬂammation (score 2 to 3) and interobserver and intra-
observer agreement was good.62 High-grade inﬂammation
at the invasive margin was found to be a strong inde-
pendent prognostic factor for survival in Dukes A and B
colorectal carcinomas.62 The prognostic value of the
Klintrup-Ma¨kinen score has subsequently been validated in
independent cohorts.63–67
A comprehensive and detailed approach to TIL
scoring in colorectal carcinoma developed by Galon
et al68 has attracted international attention.69 An initial
study by this group in 2005 conﬁrmed the prognostic
value of a semiquantitative H&E assessment of TILs in
colorectal cancer and performed a detailed analysis of the
lymphocyte subsets involved using IHC-based digital
quantitation, ﬂow cytometry and mRNA proﬁling.70
Subsequent demonstration of the marked prognostic
impact of a CD3+ T cell inﬁltrate in colorectal cancer71
was followed by development of the “Immunoscore”
which uses CD8 IHC to mark cytotoxic T cells and
CD45RO to mark memory T cells, which are scored in
hotspots selected from the invasive margin and central
tumor.72 This Immunoscore was strongly predictive of
disease free, disease speciﬁc and overall survival, and
found to be superior to the traditional TNM staging
system of the AJCC/UICC,72 conﬁrmed in further studies
by the same research group.73 More recently, on the basis
of antibody performance, the Immunoscore was modiﬁed
to include CD3 rather than CD45RO,41 which has also
been demonstrated to be predictive of distant meta-
stasis,39 and show superior prognostic value to MSI
status.74 Recently, initial results were presented in
abstract form from a worldwide taskforce established to
prospectively validate the Immunoscore.75 The assay was
reportedly reproducible across the 23 participating insti-
tutions, and the primary endpoints of the study were
reached, demonstrating a signiﬁcantly longer time to
recurrence in patients with a high Immunoscore at the
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invasive margin.75 Full results of this important interna-
tional collaboration are eagerly awaited. It is emphasized
that this review provides a framework for TIL assessment
and should be considered complementary to all other
important evolutions such as the Immunoscore.
The relative beneﬁts and limitations of semi-
quantitative H&E assessment compared with digital quan-
titation of IHC stained slides in colorectal carcinoma have
begun to be addressed.65–67 The digital image analysis
software used by Galon et al was developed in-house and is
0-10% stromal TILs 20-40% stromal TILs 50-90% stromal TILs
Step 1: Select tumor area
Step 2: Define stromal and intra-tumoral areas
Step 3: Scan at low magnification
Step 4: Determine type of inflammatory infiltrate
Step 5: Assess the percentage TILs
Include area 
within 
tumor 
borders
Do not include 
immune 
infiltrate 
outside 
of the tumor 
Stromal TILs 
(sTILs)
Intra-
tumoral
TILs (iTILs)
Mononuclear
stromal
TILs 
infiltrate
Do not include
granulocytes
in necrotic 
areas
FIGURE 1. Applying the proposed standardized methodology to evaluate tumor infiltrating lymphocytes (TILs) in melanoma. Although
traditional scoring systems have only considered intratumoral TILs in melanoma, both stromal and intratumoral TILs may be evaluated in
the research setting. Areas of necrosis or ulceration are excluded.
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not publically available for independent validation and
comparison with other methodologies.76 However, largely
concordant results have been reported using other image
analysis software (reviewed in Mei et al77). Va¨yrynen et al66
performed digital quantitation of IHC-deﬁned lymphocyte
subsets and a manual Klintrup-Ma¨kinen score of TILs, and
found strong correlation between all IHC-based counts and
the Klintrup-Ma¨kinen grade, supporting an overall
immune assessment. Richards et al65 compared a manual
semiquantitative approximation of the Galon Immuno-
score with the Klintrup-Ma¨kinen grade, and found similar
prognostic information was provided by both method-
ologies. However, a recent comparison by the same group
showed additional prognostic information was provided by
the manual semiquantitative approximation of the Galon
Immunoscore when compared with the Klintrup-Ma¨kinen
score in whole sections of 246 stage 1 to 3 colorectal can-
cers.67 A detailed cost-beneﬁt analysis of any additional
prognostic information provided by digital IHC-based
scoring is needed to justify the additional time and
resources required to perform the immunohistochemical
assays, implement slide scanning capabilities and develop
image analysis software. Furthermore, additional direct
comparison of the Galon Immunoscore by independent
groups using diﬀerent technologies, manual approximation,
or Klintrup-Ma¨kinen grading may allow deﬁnition of the
most appropriate balance between simplicity and depth of
information. As has been performed in invasive breast
cancer and lung cancer, TILs assessment as part of a
treatment-related randomized controlled trial can provide
high level evidence of prognostic and predictive value, and
could be considered in colorectal carcinoma.
In addition to prognostic information, TILs assessment
in rectal cancer may help to predict the degree of response to
neoadjuvant chemoradiotherapy. This has been investigated
in a number of studies, all using IHC to delineate diﬀerent
lymphocyte subsets.78–83 Yasuda et al81 found high numbers
of CD8+ TILs in the pretreatment biopsy to be predictive of
high histologic regression grade following chemoradiotherapy
in multivariate analysis, while Shinto et al83 found the CD8/
FOXP3 ratio to be predictive of treatment response. Similar
results were found in a univariate analyses.78–80 McCoy et al82
found a low stromal Treg count to be associated with tumor
regression, but not with overall survival. To the best of our
knowledge, this question has not been comprehensively
addressed using semiquantitative H&E-based scoring such as
the Klintrup-Ma¨kinen grade.
TILs IN UPPER GASTROINTESTINAL TRACT
CARCINOMAS
As a group, carcinomas of the stomach, pancreas, and
liver are relatively common, and also account for a dis-
proportionately high number of cancer deaths.84 Chronic
inﬂammation due to infection and other causes is at least
partly responsible for many cases. Treatment of metastatic
disease with chemoradiotherapy generally has modest
eﬀects, and initial trials of immunotherapy agents in this
group of tumors have reported mixed success,85,86 sug-
gesting the need for predictive biomarkers and a personal-
ized approach to the use of these agents.
Gastric Carcinoma
Gastric cancer is notable for its associations with
infection (Helicobacter pylori, Epstein-Barr virus—EBV),
chronic inﬂammation, and genomic instability (both MSI
and chromosomal instability).87 EBV-associated gastric
carcinoma typically shows a particularly high immune
inﬁltrate and accounts for a high proportion of the histo-
logic subtype known as lymphoepithelioma-like carcinoma
or gastric carcinoma with lymphoid stroma.88 It is thought
that the improved prognosis seen in EBV-associated gastric
cancer may be related to the high proportion of
lymphoepithelioma-like carcinoma in this group, rather
than the presence of EBV itself.89 Similar to colorectal
carcinomas, gastric carcinomas with MSI due to deﬁcien-
cies in DNA mismatch repair (dMMR/MSI-high) contain
high mutational loads, display a prominent lymphocytic
inﬁltrate, and are associated with improved prognosis.88
Assessment of gastric cancer TILs on H&E sections
has been reported in few studies. Kang et al90 assessed the
prognostic value of TILs among EBV-associated gastric
carcinomas using a modiﬁcation of the International
Immuno-Oncology Biomarkers Working Group guidelines
for breast carcinoma.1 sTILs were found to be an inde-
pendent prognostic factor for recurrence free survival but
not overall survival, while iTILs were not signiﬁcantly
associated with either recurrence free or overall survival.90
Giampieri et al91 used a similar approach and found that
sTILs were signiﬁcantly associated with dMMR status, but
that both sTILs and dMMR status were independent
favorable prognostic factors in a multivariate model.
Studies of immunohistochemical markers of immune
cells have been reported more often, singly and in combi-
nation. Inﬁltration by CD3+ and CD8+ T cells,92,93
CD20+ B cells94 and expression of the chemokine receptor
CXCR395 have been reported to correlate with improved
prognosis. Conﬂicting results have been seen for FOXP3+
Tregs, which in some studies are associated with improved
prognosis,96,97 and in others, a worse prognosis.98,99
Expression of the chemokine receptor CCR799 and immune
checkpoint molecule PD-L1100 have also been associated
with worse prognosis in gastric cancer. These studies,
reviewed by Solinas et al,101 although predominantly small
and retrospective with varying methodologies, appear to
support a favorable prognostic role of an active cytotoxic
immune response, and an unfavorable role of an exhausted
or suppressive immune response in gastric carcinoma.
Both dMMR/MSI-high and EBV-associated gastric
cancers have been proposed as candidates for immune
checkpoint inhibitor therapy,102,103 as both types are asso-
ciated with prominent host immune responses. The high
mutational load in dMMR/MSI-high cancers is thought to
result in high immunogenicity,104 as discussed further
below. EBV-associated gastric cancers show extreme levels
of hypermethylation, causing epigenetic silencing of many
tumor suppressor genes.103 In addition, PD-L1 expression
in gastric carcinoma appears to correlate with high immune
cell inﬁltration, MMR deﬁciency and the EBV-associated
subtype.100,105,106 Further evaluation in large clinical trials
is needed to conﬁrm the prognostic value of TILs in gastric
cancer, and to assess the potential value of TILs as a bio-
marker for immune checkpoint inhibition and other
immunotherapy approaches.
Pancreatic Carcinoma
Pancreatic ductal adenocarcinomas typically have
abundant desmoplastic stroma, which contributes to
tumorigenesis,107 interacts with immune and inﬂammatory
cells,108 and will be important to consider in the histologic
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assessment of TILs. Despite the recent proposal of an
“immunogenic” subtype of pancreatic ductal adenocarci-
noma identiﬁed through integrated genomic analysis,109
TILs in pancreatic cancer have received relatively little
attention. There are few published studies examining TILs
in pancreatic adenocarcinoma on H&E sections and prog-
nosis. The presence of intratumoral tertiary lymphoid
structures, as judged by pathologists, was associated with
longer overall and disease-free survival in one study.110
Hart et al111 scored intratumoral lymphocytes as high or
low on H&E sections in 63 patients, but found no associ-
ation between TILs and survival.
Immunohistochemical studies of the tumor micro-
environment in pancreatic carcinoma have found that high
levels of tumor associated M2 macrophages marked by CD68,
CD163, and CD204, neutrophils marked by CD66b, and
FOXP3+ Tregs correlated with worse prognosis.
112,113
Improved prognosis was seen with high levels of inﬁltration by
CD3+, CD8+ or CD4+ T cells and CD20+ B cells.113–115
Further histologic characterization of the proposed immuno-
genic subtype of pancreatic ductal adenocarcinoma will be of
value to inform forthcoming immunotherapy clinical trials.
Hepatocellular Carcinoma
Many cases of hepatocellular carcinoma are causally
linked to chronic inﬂammation, with viral hepatitis, alco-
hol, and nonalcoholic steatohepatitis as major underlying
contributors. Chronic inﬂammation can be seen as the
persistence of an ineﬀective immune response, and is asso-
ciated with the development of an immunosuppressive
environment with high expression of immune checkpoint
molecules, impaired antigen presentation, and the presence
of Tregs.
116 Hepatocellular carcinomas have highly variable
amounts of tumor stroma, with some cases having very
little, which will need to be factored into the assessment of
stromal TILs. Marked inﬂammatory cell inﬁltration on
H&E assessment of hepatocellular carcinomas was reported
to be associated with improved survival.117 Inﬁltration by
FOXP3+ Tregs was again found to be associated with a
worse prognosis,118 whereas an improved prognosis was
seen with cytotoxic T cell and B cell inﬁltration.119,120 Ini-
tial results of immunotherapy trials show moderate
responses of hepatocellular carcinoma to immune check-
point inhibition, and further investigation of combination
approaches is underway.116
TILs IN NON–SMALL CELL LUNG CARCINOMA
The immune microenvironment in non–small cell lung
cancer has been extensively studied and detailed descrip-
tions exist in the literature.121,122 Similar to colorectal
cancer, inclusion of an IHC-based “Immunoscore” into the
traditional TNM staging system has been proposed, fol-
lowing evidence of a signiﬁcant prognostic impact of TILs
in non–small cell lung carcinoma.123 Like melanoma, non–
small cell lung carcinoma often contains a high somatic
mutation burden and immune checkpoint inhibitors are a
promising therapeutic advance.124–128 The immune system
clearly plays an important role in the development, pro-
gression and treatment of non–small cell lung cancer, and
assessment of the immune inﬁltrate is of great interest to
clinicians and researchers.
An excellent and extensive review of the prognostic
impact of diﬀerent innate and adaptive immune cell subsets
in non–small cell lung cancer, as well as tertiary lymphoid
structures and immune checkpoint molecule expression, can
be found in Remark et al.121 In summary, cytotoxic T cells,
natural killer cells, mature dendritic cells and M1 macro-
phages have largely been associated with improved prog-
nosis, Tregs have been associated with poorer prognosis, and
inconclusive results have been found for neutrophils and
B cells.121 Geng et al129 have performed a meta-analysis of
studies investigating the prognostic impact of TILs in lung
cancer patients, including 29 studies involving 8600 patients
with non–small cell lung carcinoma. Only 3 included studies
addressed “generalized TILs” based on H&E assess-
ment,130–132 discussed further below. The majority of
included studies used IHC to deﬁne T cell subsets, including
CD3, CD8, CD4, and FOXP3.129 Overall, CD8+ cell
density in sTILs and in iTILs were associated with
improved overall survival, with similar results seen for
CD3+ cell density.129 CD4+ T cells were only associated
with overall survival when assessed in the tumor stroma
rather than the tumor cell nests, while FOXP3+ Tregs in the
tumor stroma were associated with poorer progression free
survival.129 Sixteen of these studies, along with an addi-
tional 8 studies, were included in a meta-analysis by Zeng
et al.133 These authors concluded that high levels of CD8+,
CD3+, and CD4+ TILs had prognostic signiﬁcance for
both overall survival and recurrence.133 Of note is the
moderate to signiﬁcant heterogeneity identiﬁed in both of
these meta-analyses, as well as the retrospective nature of
the included studies, many of which had incomplete data
with regard to important prognostic factors.129,133 In
addition, the lack of standardized TILs assessment and
arbitrary cut-points may reduce the validity of combining
data in this manner.
In contrast to the Immunoscore developed for color-
ectal carcinoma, many of the studies of IHC-based TIL
subset assessment in non–small cell lung carcinoma use a
manual semiquantitative approach developed in studies of
tissue microarrays by Al-Shibli et al,134 in which the per-
centage of the nucleated cells showing positive staining for
the marker in question is estimated.134–144 Diﬀerent cutoﬀs
are used to deﬁne “low” and “high” for each marker, and
for the epithelial/tumor nest compartment and the stromal
compartment, according to the staining distribution.134
Other studies have used an absolute count of positive cells
per millimeter square, determined by digital image anal-
ysis145–150 or manual counting.151–157 On the basis of their
previous work, Donnem et al138 recently demonstrated that
the stromal CD8+ T cell density, scored on a manual
semiquantitative 4-point scale, has independent prognostic
value and can stratify patients within each TNM stage. This
paper was followed by a proposal to introduce an IHC-
based “TNM-Immune” staging system into clinical use for
non–small cell lung cancer, as has been proposed for col-
orectal cancer.123
In contrast to this IHC-based method, Brambilla
et al158 recently reported a large analysis of the prognostic
impact of TILs in non–small cell lung carcinoma, per-
formed as part of the LACE-Bio pool of 4 randomized
clinical trials. Samples from discovery and internal vali-
dation cohorts were evaluated for lymphocytic inﬁltration
by H&E assessment and scored on a 4-point semi-
quantitative scale which was collapsed into binary “intense”
and “nonintense” categories, where an intense inﬁltrate was
deﬁned as mimicking a lymph node involved by cancer
metastasis.158 Overall agreement was good when binary
classiﬁcation was used.158 Intense lymphocytic inﬁltration
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was found to be an independent prognostic variable for
overall survival and disease-free survival on multivariate
analysis in both the discovery and validation sets.158 Nei-
ther tumor histology nor treatment showed signiﬁcant
interactions with degree of lymphocytic inﬁltration and
TILs did not predict beneﬁt to platinum-based adjuvant
chemotherapy.158 Three studies have used a similar semi-
quantitative H&E-based scale and found high lymphocytic
inﬁltration to correlate with recurrence free sur-
vival,130,131,159 however no prognostic impact was found in
a 2 separate studies using diﬀerent subjective H&E assess-
ments.132,160 Mignon et al161 recently presented results
demonstrating that scoring percentage stromal TILs on
H&E was highly reproducible and showed prognostic sig-
niﬁcance, particularly in KRAS mutant non–small cell lung
cancer. However, scoring percentage iTILs on H&E was
not reproducible between pathologists and failed to dem-
onstrate prognostic signiﬁcance.161
Further research may be required to clarify the
potential importance of separating the stromal and intra-
epithelial compartments, as advocated by Donnem et al,123
compared with an overall assessment as preferred by
Brambilla et al.158 Issues of reproducibility in iTILs scoring
must also be taken into consideration. In addition, con-
sideration of potential diﬀerences at the invasive margin
and in the central tumor has not been extensively studied in
non–small cell lung carcinoma in contrast to colorectal
carcinoma. A prospective evaluation of the lung Immuno-
score, potentially using digital image analysis, has been
proposed.123 Quantitative immunoﬂuorescence has also
been used to demonstrate the prognostic value of TIL
subsets in this setting.132 An important aspect of the
immune response to tumors, the formation of tertiary
lymphoid structures, may not be captured by an overall
H&E-based TILs assessment or by IHC-based hotspot
assessment. The prognostic importance of tertiary lym-
phoid structures has been well studied in non–small cell
lung cancer,121,147,162 and their presence correlates with an
activated cytotoxic T-cell response, indicating an important
role of these local organized lymphoid structures in coor-
dinating the immune response to tumors.147 Head-to-head
comparison of the IHC-based Immunoscore and the overall
H&E assessment, with consideration of the inclusion of
additional features such as tertiary lymphoid structures,
would also be of value in progressing toward a consensus
for TILs assessment in non–small cell lung cancer. An
approach to features particular to lung carcinoma such as
lepidic growth and aerogenous spread is found in the
accompanying tutorial, available in Supplementary File 2,
Supplemental Digital Content 2 (http://links.lww.com/
PAP/A18). Preexisting alveolar macrophages would be
excluded from a TIL assessment in non–small cell lung
carcinoma, while the sTILs compartment would include the
ﬁbrovascular cores of papillary structures (Fig. 2).
Assessment of the immune response to non–small cell
lung carcinoma is of particular interest following accumu-
lating evidence of the eﬃcacy of immune checkpoint
inhibitor therapy for this indication.124–128 Although stud-
ies of PD-1 inhibitors nivolumab and pembrolizumab have
focused on tumor cell PD-L1 expression as a predictive
biomarker,124,125,127 studies of the PD-L1 inhibitor atezo-
lizumab have also shown predictive value of PD-L1
expression on tumor inﬁltrating immune cells.126
Response to atezolizumab also correlated with high
expression of eﬀector T-cell and interferon-g associated
gene signatures in tumor tissue.126 Although further dis-
cussion of the issues surrounding PD-L1 IHC is beyond the
scope of this article, it is clear that a standardized method
of assessing and quantifying the immune inﬁltrate in
tumors is needed to then reliably assess immune cell PD-L1
expression.
Less is known about the immune microenvironment of
pleural malignant mesothelioma, but the potential eﬀect of
TILs on mesothelioma prognosis is beginning to be
described. Early IHC-based studies suggested a favorable
prognostic eﬀect of TILs in mesothelioma.163,164 More
recently, in a cohort of 329 pleural malignant mesothelioma
cases comprising video-assisted thoracoscopic surgery
pleurodesis biopsies and resection specimens, Russell,
Thapa and John (personal communication) assessed the
percentage of stromal TILs and the presence or absence of
tertiary lymphoid structures. Interestingly, the sTILs score
was strongly negatively correlated with survival; however,
the presence of tertiary lymphoid structures was inde-
pendently associated with better survival in multivariate
analysis. A tutorial demonstrating the proposed approach
to TILs assessment in pleural malignant mesothelioma is
available online in Supplementary File 3, Supplemental
Digital Content 3 (http://links.lww.com/PAP/A19).
TILs IN GYNECOLOGIC CARCINOMAS
Endometrial Carcinoma
Relatively little is known about the prognostic sig-
niﬁcance of TILs in endometrial carcinoma, with many
studies focusing instead on the value of TILs to predict MSI
status. With increasing recognition of the frequency of
Lynch syndrome among women with endometrial cancer
and the advent of reliable immunohistochemical screening,
assessment of TILs is receiving less attention. However,
interest has been renewed following identiﬁcation of the
ultramutated POLE subtype of endometrial carcinoma and
the potential utility of immune checkpoint inhibitors.
Approximately 10% to 20% of endometrial carcino-
mas display MSI due to either epigenetic silencing or
germline mutations in DNA mismatch repair genes (Lynch
syndrome).165,166 Similar to colorectal carcinoma, initial
screening guidelines incorporated clinical and pathologic
Exclude 
alveolar 
macrophages
sTILs
sTILs
sTILs
FIGURE 2. When assessing tumor infiltrating lymphocytes (TILs) in
non–small cell lung carcinoma, include lymphocytes in the fibro-
vascular cores of papillary structures (marked sTILs), and exclude
alveolar macrophages. Please see this image in color online.
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features (reviewed in167). Shia et al168 found high TILs
counts and the presence of peritumoral lymphocytes to be
predictive of deﬁcient MMR in endometrial carcinomas,
with a sensitivity of 85% and speciﬁcity of 46%. Only
lymphocytes within tumor cell nests (ie, intraepithelial)
were counted as TILs, and an absolute count of 10 H&E
stained high power ﬁelds was obtained.168 This method and
the proposed cutoﬀ of 40 lymphocytes per 10 high power
ﬁeld were used in subsequent studies, which showed similar
results.169–172 As for colorectal cancer, the reported sensi-
tivities of even multivariate models are now considered
insuﬃcient for screening for MMR defects.167,173
A recently recognized subgroup of endometrial can-
cers has a very high mutation rate due to deﬁciencies in
DNA proofreading.174 POLE mutations are found in
approximately 7% of endometrial carcinomas, resulting in
loss of DNA polymerase epsilon and ineﬀective DNA
proofreading.175 This group of POLE ultramutated endo-
metrial carcinomas appears to have an improved prognosis,
particularly in high-grade cancers, and shows particular
histologic features as illustrated in Figure 3.174,176,177
Howitt et al178 found that POLE-mutated endometrial
carcinomas had very high predicted neoantigen loads, and
that POLE and MSI tumors had higher TILs and higher
PD-L1 expression on immune cells than microsatellite sta-
ble tumors. Similar histologic ﬁndings were reported by
Hussein et al179 and van Gool et al.180 Given the initial
positive results of immune checkpoint inhibition in MSI
tumors,102 similar responses may be predicted in POLE
ultramutated tumors, although this has not yet been clin-
ically tested to our knowledge. The recognition of POLE
tumors has prognostic value and potential predictive value,
and as there is not yet a widely available immunohis-
tochemical marker to screen cases, histologic features
including TILs may prove useful to identify cases for fur-
ther testing.
Robust evidence of the clinical validity of TILs
assessment for prognosis in endometrial carcinoma remains
to be demonstrated. Intraepithelial CD8+ T cell density
has shown independent prognostic signiﬁcance in initial
studies,181–183 and stromal CD3+ T cells may also have
prognostic value.184 Workel et al demonstrated that
CD103, a marker discussed further below, deﬁned intra-
epithelial CD8+ PD-1+ lymphocytes, and that high
numbers of these iTILs were associated with improved
prognosis in patients with high-risk endometrial adeno-
carcinoma.185 High Treg counts were associated with poorer
disease-free survival in the study of Yamagami et al.186
Further work in large, high quality studies is needed to
conﬁrm the prognostic signiﬁcance of TILs in endometrial
carcinoma, which may have signiﬁcant interactions with
MSI and POLE status. A tutorial outlining the proposed
approach to scoring TILs in endometrial cancer is available
online in Supplementary File 4, Supplemental Digital
Content 4 (http://links.lww.com/PAP/A20).
Ovarian Carcinoma
A seminal paper published in 2003 by Zhang et al187
established the prognostic signiﬁcance of TILs in ovarian
carcinoma. In the intervening years, evidence has accumu-
lated largely in support of this ﬁnding and has reﬁned the
clinicopathologic features associated with a robust TIL
response.
In their study of 186 ovarian carcinomas, Zhang
et al187 found that the presence of any intraepithelial T cells,
as assessed on CD3 IHC, was an independent favorable
prognostic factor on multivariate analysis, with striking
diﬀerences in progression free and overall survival between
the 2 groups. Both manual counting and digital image
analysis were used to determine the number of T cells per
high power ﬁeld, averaged from a total of 15 to 20 high
power ﬁelds.187 Both iTILs and sTILs were assessed,
however only results for iTILs were reported.187 While
some studies have since reported no association between
TILs and prognosis in ovarian carcinoma,188,189 a recent
meta-analysis of 10 studies involving 1815 patients found
women with ovarian cancers lacking intraepithelial TILs
had a risk of dying 1.53x that of women with tumors
containing CD8+ TILs (95% conﬁdence interval, 1.22-
1.93).190 This pooled hazard ratio was higher, up to 2.67
(95% conﬁdence interval, 2.02-3.53), when studies using a
higher cutoﬀ to deﬁne “TIL negative” were analyzed.190
The authors concluded that >5 CD8+ TILs per 200
high power ﬁeld should be used to deﬁne “TIL positive” in
ovarian carcinoma.190 To the best of our knowledge, no
FIGURE 3. An example of an ultramutated endometrial carci-
noma with POLE mutation. Characteristic histologic features
include expansile growth with a pushing border, solid areas and
serous-like morphology (A), as well as high FIGO grade and
prominent stromal and intratumoral lymphoid infiltrate (B).
Please see this image in color online.
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study has formally compared the information gained from
quantitative IHC-based assessment to that potentially
obtained from semiquantitative H&E-based scoring.
As has been reported in other tumor types, diﬀerent
lymphocyte subsets may have diﬀerent impacts on the
progression and prognosis of ovarian carcinoma. In the
meta-analysis by Hwang et al,190 CD8 was found to have a
more consistent and stronger association with overall sur-
vival than CD3. Cytotoxic T cells marked by TIA-1 and
granzyme B have also been shown to positively correlate
with survival.191 Interestingly, the presence of CD20+ B
cells and plasma cells co-localized with T cells appears to
increase the positive prognostic eﬀect of TILs above that
seen with CD8+ T cells alone.192,193 Plasma cells were
predominantly seen in the stromal compartment, often in
association with organized tertiary lymphoid structures,193
which have been shown to correlate with improved prog-
nosis in many tumor types.194 In contrast, conﬂicting
results have been seen with regard to intraepithelial
FOXP3+ Tregs, with studies showing both positive
191,195
and negative196–198 eﬀects on survival in ovarian carcinoma.
The location of TILs may have particular signiﬁcance in
ovarian carcinoma. Following the original description of
intraepithelial TILs in ovarian carcinoma,187 most studies
have focused on the epithelial compartment. Stumpf et al199
reported that high numbers of iTILs, but not sTILs, were
associated with improved survival. Similar ﬁndings
were reported by Darb-Esfahani et al.200 Webb et al201 have
demonstrated that the integrin CD103, which binds to
E-cadherin expressed by epithelial cells, is highly expressed by
intraepithelial eﬀector T cells in ovarian carcinoma, and
suggested that it is these CD103+ T cells that contribute to
the improved prognosis seen with high levels of TILs. Sim-
ilarly, Bosmuller et al202 found CD103 added prognostic
value to conventional T cell markers in the assessment of
TILs in ovarian carcinoma. However, 2 studies have reported
important prognostic value of TILs in the stromal compart-
ment, similar to that seen in the epithelial compartment.203,204
In addition, the important interaction between T cells, B cells
and plasma cells described by Nielsen et al192 and Kroeger
et al,193 and the formation of tertiary lymphoid structures,
take place predominantly in the tumor stroma. Therefore
although intraepithelial TILs clearly have well-demonstrated
prognostic signiﬁcance in ovarian carcinoma, the stromal
compartment should also be considered when evaluating
TILs in these tumors. A tutorial on TILs assessment in
ovarian carcinoma is available in Supplementary File 5,
Supplemental Digital Content 5 (http://links.lww.com/PAP/
A21). Figure 4 illustrates a range of sTILs percentages in
ovarian carcinoma as a reference.
Neoadjuvant chemotherapy for ovarian carcinoma is a
controversial area, and selection of patients who should
receive neoadjuvant chemotherapy rather than undergo
primary debulking surgery is currently challenging.205–207
Pretreatment biopsies matched with posttreatment resec-
tion specimens provide valuable opportunities for examin-
ing modulation of the immune response by chemotherapy
and evaluating potential predictors of response to neo-
adjuvant chemotherapy. Early work suggests that TILs
increase following neoadjuvant chemotherapy, both cyto-
toxic and regulatory T cells.208,209 Importantly, many TILs
postneoadjuvant chemotherapy express CTLA-4, PD-1,
and PD-L1,208 and tumor cell expression of PD-L1 may
also be induced by neoadjuvant chemotherapy. These
molecules may be considered markers of T cell exhaustion
in the appropriate context, and expression of these markers
may support the use of immune checkpoint inhibitors fol-
lowing chemotherapy to reawaken the immune response.208
Lo et al210 also described an increase in immune inﬁltration
following neoadjuvant chemotherapy in those tumors
showing some degree of baseline TILs. However, TIL
negative tumors tended to remain TIL negative following
neoadjuvant chemotherapy, suggesting that assessment of
TILs in pretreatment biopsies may help to identify
“immunologically inert” tumors, which would be unlikely
to respond to immunotherapy approaches.210 Inclusion of
TILs as planned biomarker analyses in future randomized
clinical trials, as has been performed in breast carcinoma,
may help to reveal any value of TILs in predicting response
to neoadjuvant chemotherapy.
The majority of ovarian malignancies are high-grade
serous carcinomas which often present at high stage and
have a dismal prognosis.211 The prognostic impact of TILs
appears limited to high-grade serous ovarian carcino-
mas;191 however, numbers of other subtypes including
endometrioid, clear cell and mucinous carcinomas were
small. Interestingly, the association between TILs and
MMR status seen in endometrial carcinoma does not
appear to be recapitulated in Lynch syndrome–associated
endometrioid ovarian carcinoma.212 Approximately half of
high-grade serous ovarian carcinomas will show defects in
the homologous recombination pathway, most commonly
BRCA1 inactivation through germline or sporadic muta-
tion or methylation.213 Higher levels of TILs are seen in
BRCA1 mutated ovarian carcinomas,214–217 which also
correlate with the immunoreactive molecular subtype as
deﬁned by The Cancer Genome Atlas.213,218 TILs are
included in a set of histologic criteria suggested to predict
BRCA1 mutations in high-grade serous ovarian carcino-
mas,219 which demonstrated a high negative predictive
value but low positive predictive value. Conﬂicting results
have been obtained regarding the level of TILs in BRCA2
mutated ovarian carcinomas and those showing other
defects in the homologous recombination path-
way.214,216,218 Parallels may be drawn to BRCA1/2 asso-
ciated breast carcinoma in which higher lymphocytic inﬁl-
trates are seen in BRCA1 mutated cancers, while BRCA2
associated breast carcinomas do not have a characteristic
morphology.220,221 Why BRCA1 associated tumors show
high TILs while tumors with other homologous
recombination-pathway defects including BRCA2 do not,
is yet to be conclusively explained. The unique function of
BRCA1 as a transcription factor, links between BRCA1
mutations and copy number alterations, or potential
cancer-testis antigen expression, may warrant further
investigation in this context.222
TILs IN HEAD AND NECK SQUAMOUS CELL
CARCINOMA
Head and neck squamous cell carcinoma encompasses a
heterogenous group of tumors arising in diﬀerent subsites
within the upper aerodigestive tract, including the oral cavity,
the oropharynx, larynx, and hypopharynx.While many cancers
are etiologically related to the traditional risk factors of tobacco
and alcohol, others are associated with human papilloma virus
(HPV) infection. These HPV-related tumors typically arise in
the oropharynx, are found in younger, never-smokers and are
associated with better prognosis. Following Wolf et al’s223
description in 1986 of improved outcome in tumors with
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increased lymphocyte inﬁltration in a small cohort of patients
with oral cavity squamous cell carcinoma, many studies have
described immune cell inﬁltrates in head and neck squamous
cell carcinoma and correlated these with outcome.224–226 While
the presence of TILs has generally been associated with
improved prognosis, diﬀerences have been reported according
to anatomic subsite, tumor compartment (intratumoral vs.
stromal) and importantly in HPV-positive (HPV+) compared
with HPV-negative (HPV) head and neck squamous cell
carcinomas.
FIGURE 4. Examples of a range of stromal tumor infiltrating lymphocytes percentages in high-grade serous ovarian carcinoma. Please
see this image in color online.
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Biological and immunologic diﬀerences exist between
tumors arising in diﬀerent anatomic subsites of the head
and neck. Oropharyngeal squamous cell carcinomas, which
arise from the squamous epithelium associated with the
lymphoid tissue of the tonsils and base of tongue, have
higher numbers of inﬁltrating iTILs and sTILs compared
with other subsites.227 The preexisting background lym-
phoid stroma will clearly complicate TIL assessment in
these tumors, and an approach similar to that used to assess
metastatic deposits in lymph nodes is recommended, that is,
to discount any established lymphoid stroma and focus on
iTILs in this setting if no desmoplastic stroma is present.
Alternatively, it has been suggested that this preexisting
lymphoid stroma is not simply a bystander, but may con-
tribute to the improved prognosis of oropharyngeal
squamous cell carcinomas compared with squamous cell
carcinomas in other regions of the head and neck.228 This
interesting question requires further investigation.
Importantly, within the subset of oropharyngeal tumors,
there are signiﬁcant genomic and immunologic diﬀerences
between HPV+ and HPV tumors. Many studies have
reported a higher number of TILs, in particular CD8+ T
cells within tumor and stroma, in HPV+ tumors compared
with HPV tumors.229–233 Increased numbers of FOXP3+
Tregs, PD-1
+ T cells and CD20+ B cells within immune
inﬁltrates in HPV+ tumors have also been described.234,235
Using gene expression analysis, Wood et al236 found
increased expression of genes encoding PD-1, CTLA-4, and
TIM3 in HPV+ tumors, indicating an exhausted immune
response. Interestingly, a B cell signature distinguished
HPV+ from HPV tumors, suggesting B cells rather than T
cells account for the increased TILs seen in HPV+
tumors.236 Immunohistochemical studies have shown CD8+
and FOXP3+ TILs to signiﬁcantly correlate with improved
prognosis in oropharyngeal HPV+ tumors229–236 and
probably also HPV tumors.233,236
Genomic analyses have also highlighted the impor-
tance of immune cell inﬁltrates in head and neck squamous
cell carcinomas. Using unsupervised clustering of gene
expression data, Keck et al237 identiﬁed immune mesen-
chymal subtypes of HPV+ and HPV– head and neck
squamous cell carcinomas, which were associated with
increased expression of immune markers, increased CD8+
TILs and improved outcomes. Mandal et al,238 in an
analysis of transcriptome data from 280 head and neck
squamous cell carcinomas from The Cancer Genome Atlas,
found that HPV+ tumors had higher levels of T cell and
overall immune gene signatures, together with higher
expression of markers of immune activation such as gran-
zyme B and perforin. Patients with tumors showing high
immune gene expression had superior overall survival, and
when controlled for HPV status, CD8+ T cells were sig-
niﬁcantly associated with survival. Tregs and CD56
dim NK
cells were also associated with favorable prognosis.238
Studies including tumors from other subsites have also
identiﬁed improved outcome with higher immune cell
inﬁltrates. In tumors of the oral cavity, a 3-tiered qual-
itative assessment of the lymphocytic inﬁltrate on H&E
sections was found to be an independent prognostic factor
for local recurrence and overall survival in multivariate
analysis.239 Similar favorable ﬁndings were seen with
increased intratumoral or stromal CD8+ cells,240 while
increased numbers of FOXP3+ Tregs may have detrimental
eﬀects oral cavity squamous cell carcinoma outcome.241
Vassilakopoulou et al242 and Wang et al243 applied the
consensus TILs scoring guidelines from the International
Immuno-Oncology Biomarkers Working Group1 to lar-
yngeal squamous cell carcinoma, and both studies found
that the sTILs score was an independent prognostic factor
for disease-free survival and overall survival.
Studies using semiquantitative scoring of IHC to
describe TILs in head and neck squamous cell carcinomas
have suggested a potential predictive role of inﬁltrating
CD3+ and CD8+ T cells.244,245 High levels of CD3+ and
CD8+ iTILs correlated with improved outcome following
deﬁnitive chemoradiotherapy, while sTILs showed no sig-
niﬁcant association.244 In a subsequent cohort of 161
patients treated with surgery followed by adjuvant chemo-
radiation, CD3+ and CD8+ TILs in the stromal, intra-
tumoral, and tumor periphery compartments were all
associated with improved outcome.245 Large prospective
clinical trials of treatment modalities would be an ideal
setting to further investigate the potential role of TILs in
predicting the eﬃcacy of chemoradiation in head and neck
squamous cell carcinomas.
As discussed in a recent review,224 TILs in head and
neck squamous cell carcinomas may not yet be ready for
implementation as a clinical biomarker. Studies evaluating
TILs in head and neck squamous cell carcinomas have been
limited by small cohort sizes, retrospective approaches,
inclusion of heterogenous populations, univariate analyses,
and lack of standardized methodology for TIL quantiﬁca-
tion. This argues for the need for larger studies with pro-
spective validation that take into account factors such as
tumor site and HPV status, and which also determine the
relationship between immune inﬁltrates and immune regu-
latory markers such as PD-L1. This will be particularly
important in the context of predicting response to immune
therapies such as PD-1 or PD-L1 inhibitors that are
showing promising eﬃcacy in head and neck squamous cell
carcinomas.246,247 It is encouraging that diﬀerent research
groups have been able to adapt the consensus guidelines for
TILs assessment in breast cancer to head and neck squ-
amous cell carcinomas, and demonstrate signiﬁcant results
with regards to prognosis. A standardized methodology will
help to overcome many of the barriers to clinical
implementation.
TILs IN GENITOURINARY CARCINOMAS
Urothelial Carcinoma
The successful introduction of intravesical bacillus
Calmette-Guerin (BCG) therapy for high-risk nonmuscle
invasive urothelial carcinoma over the past decades can be
regarded as early proof of the potential eﬀectiveness of
immunotherapy in urothelial carcinoma.248,249 The induction
of inﬂammation and a Th1 cytotoxic immune response by
BCG administration can control in situ carcinoma and pre-
vent progression to invasive disease.249 Further support for
immunotherapy in bladder cancer has been sparked by the
recent FDA approval of the PD-L1 inhibitor atezolizumab for
use in advanced urothelial carcinoma250 and encouraging
results from early trials of PD-1 inhibitor pembrolizumab.251
Response is correlated with the expression of PD-L1 on
stromal immune cells,250,251 hence the presence of an immune
inﬁltrate in urothelial carcinoma is critical for the eﬀectiveness
of these novel treatments. The presence of TILs in urothelial
carcinoma has gained more and more interest during the last
few decades. Currently, we can discriminate 2 types of studies
on TILs in urothelial carcinoma: those focusing on the
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prognostic relevance of TILs and those focusing on TILs as
predictors of treatment response.
Studies of the prognostic relevance of TILs in uro-
thelial carcinoma, largely based on immunohistochemical
quantiﬁcation of diﬀerent TIL subsets, have returned
somewhat conﬂicting results. Several decades ago it was
reported that the presence of TILs in urothelial carcinoma
was associated with a favorable prognosis.252,253 In a ret-
rospective study on a cohort of 69 urothelial carcinoma
cases, Sharma et al254 found that high numbers of CD8+
intratumoral T cells in urothelial carcinoma correlated
with improved disease-free survival and overall survival.
The presence of FOXP3+ TILs in urothelial carcinoma
and the presence of CD3+ TILs in nonmuscle invasive
urothelial carcinoma have also been associated with a
better prognosis.255,256 In contrast, others have reported
that CD3+ and CD8+ TILs are predictive of disease
recurrence in patients with solitary low-grade nonmuscle
invasive urothelial carcinoma and that CD4+ T cells
are associated with a poor prognosis in this setting.257,258
Another study showed that high CD3+ and CD8+ T cell
inﬁltrates demonstrated trends toward better prognosis,
but that high FOXP3/CD3 and FOXP3/CD8 ratios were
correlated with poor outcomes.259 Similar observations
were made by Parodi et al,260 who reported that the
intratumoral T eﬀector/Treg cell ratio in urothelial carci-
noma patients with disease recurrence is invariably <1,
while it is always >1 in patients without recurrence.
Interestingly, PD-L1 expression on TILs was shown to be
signiﬁcantly associated with better overall survival in
urothelial carcinoma patients who subsequently developed
metastatic disease and received platinum-based chemo-
therapy.261 Studies investigating TILs as a prognostic
marker in urothelial carcinoma have been largely retro-
spective in relatively small cohorts, with variable
deﬁnitions of TILs, inclusion of iTILs and/or sTILs, and
the scoring methodology used. These inconsistencies
hamper comparisons across studies and extrapolation of
ﬁndings to clinical settings. Large studies investigating
the potential prognostic value of TILs as assessed on H&E
are lacking.
Platinum-based combination chemotherapy remains
the standard ﬁrst-line treatment for patients with metastatic
urothelial carcinoma.262 In the second-line setting, many
drugs have been tested, but none have become established
as a standard of care because of a low frequency of
response. In the context of the success of BCG immuno-
therapy, and the recent development of immune checkpoint
inhibitors as an exciting option for second-line systemic
therapy, the potential predictive value of TILs has earned
signiﬁcant scientiﬁc interest. Intravesical BCG therapy
induces an immune response, with a signiﬁcant increase of
CD3+, CD4+, and CD8+ T-cells in tissue specimens
observed after treatment, although no signiﬁcant diﬀer-
ences between responders and nonresponders have been
found.263 Several studies conﬁrmed that a large number of
tumor associated macrophages and an increased cancer
cell-to-lamina propria tumor associated macrophage ratio
were associated with a poor oncologic outcome after
BCG.264–266 These macrophages play important roles in
coordinating polarization of the immune response to either
protect or attack the tumor. Pichler et al267 reported similar
ﬁndings of an inverse correlation between tumor associated
macrophages, Tregs and T-bet
+ T-cells and disease-free
survival following BCG therapy. High levels of CD4+ and
GATA-3+ T cells were associated with improved disease-
free survival.267
The hypothesis that the immune system also plays a
role in the response of urothelial carcinoma to systemic
chemotherapy is supported by a recent study by Baras
et al,268 in which ratio of CD8+ TILs to CD25+ Tregs was
strongly associated with response to platinum-based neo-
adjuvant chemotherapy. As mentioned above, it appears
that in urothelial carcinoma the expression of checkpoint
molecule PD-L1 on the cells of the immune inﬁltrate is
more relevant in predicting response to PD-1 and PD-L1
inhibitors than expression on tumor cells.250,251 Of note is
the deﬁnition of immune cell positivity used in these clinical
trials, scoring the percentage of tumor stroma that is cov-
ered by PD-L1 positive immune cells, with a cutoﬀ of
1%.250,251 Scoring sTILs on H&E as a percentage of tumor
area is therefore easily comparable with, and translatable
into, immune cell scoring on PD-L1 IHC. The expression of
PD-L1 on stromal immune cells correlated with CD8+ T
cell inﬁltration assessed on IHC, which also correlated with
response to atezolizumab.250 Up-regulation of immune
checkpoint molecules is linked to the activation of T cells
and is dependent on their presence in the tumor micro-
environment.269 As these 2 parameters are strongly
correlated, TIL assessment alone may prove valuable in
predicting response to immune checkpoint inhibition, as
more novel agents targeting diﬀerent or multiple check-
point or stimulatory pathways are developed. An illustrated
tutorial for TILs assessment in urothelial carcinoma is
available in Supplementary File 6, Supplemental Digital
Content 6 (http://links.lww.com/PAP/A22).
Prostate Carcinoma
Traditionally, prostate cancer has not been associated
with a ﬂorid immune response and the potential of prostate
cancer to respond to immunotherapy is still questioned.270
Most reports on TILs in prostate cancer have focused on
the prognostic relevance of TILs, with fewer studies inves-
tigating the predictive value to drug therapies. Reports on
the composition of TILs in prostate cancer are hetero-
genous and sometimes conﬂicting. One study found that
TILs in prostate cancer are predominantly CD8+ T lym-
phocytes,271 while other studies reported opposite ﬁndings
with predominant populations of CD4+ T lymphocytes
and sparse CD8+ T cells.272 A pronounced presence of
CD25+ and FOXP3+ Tregs in the TIL-inﬁltrate has been
reported.272–275 Another study found that a high pro-
portion of CD8+ TILs in prostate cancer showed expres-
sion of PD-1 and had undergone a clonal expansion to an
as yet unidentiﬁed antigen.276
In prostate cancer the relationship between TILs and
survival is still unclear, although surprisingly, most
reports show evidence for a correlation between TILs and
poor prognosis. A high TIL inﬁltrate has been associated
with increased risk of recurrence,277–279 metastasis,280
and poor cancer speciﬁc survival.281 Flammiger et al282
have published the largest cohort on the prognostic eﬀect
of TILs in prostate cancer to date and concluded that
patients with either a high or very low number of CD3+
lymphocytes in tumor epithelial areas had a shorter time
to biochemical recurrence. They did not, however, inves-
tigate how the diﬀerent subsets of T lymphocytes
contributed to the clinical outcome. Ness et al283 showed
that the negative prognostic eﬀect may be mediated
primarily through CD8+ lymphocytes rather than the
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overall density of T lymphocytes as measured by CD3
positivity, while Davidsson et al284 attributed the poor
prognostic eﬀect to Tregs in the prostate cancer micro-
environment. Others have reported a correlation between
FOXP3+ TILs in prostate cancer and biochemical
recurrence,285 though Vesalainen et al286 reported that
tumors with dense TILs were associated with higher sur-
vival rates than tumors with absent or decreased TILs. In
a recent study it was found that higher CD8+ and lower
PD-1+ TIL scores correlated to a longer biochemical-
recurrence free survival in patients subjected to salvage
radiotherapy after biochemical relapse.287 The contrib-
ution of B cells to clinicopathologic features of prostate
cancer, recurrence and survival is also unclear278,282,288–290
and requires further investigation. This apparent associa-
tion between high TILs and poor prognosis in prostate
cancer contrasts with most other solid tumors, as
discussed in other sections, and requires validation in large
cohorts using a standardized methodology.
Androgen deprivation therapy is the mainstay of sys-
temic treatment for prostate cancer, and has been shown to
have immunomodulatory eﬀects, triggering an inﬂux of
CD4+ and CD8+ TILs.291,292 Despite the traditional view
of prostate cancer as a poorly immunogenic tumor, sipu-
leucel-T, an autologous dendritic cell vaccine, became the
ﬁrst cancer vaccine to receive FDA approval in 2010.293
Following the development of more eﬀective chemotherapy
for metastatic castrate resistant prostate cancer, sipuleucel-
T currently has a limited role in this setting.294 Trials of
immune checkpoint inhibition in prostate cancer have been
largely disappointing,295–297 however a small phase II trial
of pembrolizumab in enzalutamide-resistant prostate can-
cer found tumors with T cell inﬁltrates and PD-L1
expression may show more promising results.298 Further
exploration of the immune contexture of prostate cancer, its
association with prognosis and potential as an immuno-
therapy biomarker will be of great interest to clinicians and
researchers.
Renal Cell Carcinoma
Before the introduction of tyrosine kinase inhibitors
with antiangiogenic actions such as sunitinib, and mTOR
inhibitors such as everolimus, immunotherapy was the
mainstay of systemic treatment for metastatic renal cell
carcinoma.299 High dose IL-2 therapy could result in
durable complete responses but signiﬁcant toxicity limited
its application.299 Recently, excitement has grown over the
potential of immune checkpoint inhibitor therapy, with
anti-PD-1 agent nivolumab receiving FDA approval for
advanced renal cell carcinoma in 2015.300 These clinical
successes suggest that the immune system plays an impor-
tant role in the control or progression of renal cell carci-
noma, however the prognostic and predictive value of TILs
in this setting remains under investigation.
Early reports showed that TILs in renal cell carcinoma
are predominantly T cells and natural killer cells with minor
populations of B cells.301–305 T lymphocytes in renal cell
carcinoma were found to be enriched in functional CD4+
cells of the Th1 lineage and in eﬀector memory CD8+
cells.306 In addition, several populations of CD4+ and
CD8+ Tregs were identiﬁed that may synergize to locally
dampen antitumor T cell responses.306–308 Several studies
have investigated the relation between TILs and clinical
outcome in renal cell carcinoma. Interestingly, increased
TILs, both CD4+ and CD8+ T cells, appear to correlate
with tumor recurrence and poor prognosis in renal cell
carcinoma.305,309–312 Potentially of most relevance was the
ability of some studies to diﬀerentiate between the eﬀector
cytotoxic CD8+ T cells and their exhausted counter-
parts.309 When dichotomized in such a way, Giraldo et al313
were able to clearly demonstrate good prognosis with the
former CD8+ T-cell population, and poor prognosis with
the latter. Similarly, Nakano et al311 showed that TILs with
high CD8+ T cell content that exhibited high proliferative
activity were associated with improved survival among
patients with advanced renal cell carcinoma. High numbers
of FOXP3+ Tregs, both in the tumor microenvironment
and the peripheral blood, have been associated with meta-
stasis, short disease-free survival, and poor prognosis.308,314–317
The presence of CD4+CD25+FOXP3 Tregs in renal cell
carcinoma was also signiﬁcantly associated with poor out-
come.311 In clear cell renal cell carcinoma, PD-1+ TILs were
independent prognostic indicators for overall survival,315,318
however no signiﬁcant association was found in nonclear cell
renal cell carcinoma.319 Others have reported on the inde-
pendent prognostic values of concomitant quantiﬁcation of
densities of CD8+, PD-1+, and LAG-3+ lymphocytes in
addition to PD-L1/PD-L2 expression by tumor cells.313 These
somewhat confusing results from retrospective observational
studies using diﬀerent techniques require validation and
clariﬁcation.
Early data suggest that antiangiogenic targeted
therapies in renal cell carcinoma may have immunomodu-
latory eﬀects. For example, pretreatment with sunitinib
increased the ability of the investigators to expand TILs
from the tumor ex vivo.320 In a phase 1 clinical trial, the
antiangiogenic drug bevacizumab increased immune cell
inﬁltration and Th1 gene expression when combined with
atezolizumab in metastatic renal cell carcinoma.321 Data on
the potential predictive value of TILs in this setting are
limited, however in one study, higher intratumor CD8+ T
cell counts were independently associated with shorter
overall survival in patients receiving tyrosine kinase inhib-
itor therapy.322 Studies of immune checkpoint inhibitors in
renal cell carcinoma have largely focused on PD-L1
expression on tumor cells as a potential predictive bio-
marker,300,323 however data from other tumor types such as
urothelial carcinoma suggest that the immune inﬁltrate may
also have predictive value in this setting and this should be
investigated further.
TILs IN BRAIN TUMORS
The central nervous system has long been considered
an immune-privileged organ, but this view is being
increasingly challenged as it has become clear that the
immune system is active and important in many central
nervous system disorders, including neoplastic disease. A
prognostic role of TIL inﬁltration has been shown in some
small and retrospective studies for gliomas and brain
metastases (reviewed by Bienkowski et al324). The principles
of TIL assessment described for the respective primary
tumor types in this review (eg, breast cancer, lung cancer,
melanoma, etc.) are also likely to be applicable in brain
metastases (discussed further in part 1 of this review).
However, the histomorphology of most primary brain
tumors is unique and distinct from other solid cancers and
therefore speciﬁc TIL assessment algorithms may need to
be developed. Nevertheless, here, we summarize the current
knowledge on the most common primary brain tumor
types, namely gliomas and meningiomas.
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Gliomas
TILs are frequently present in gliomas, although in
most cases at relatively low densities.325 TILs in gliomas are
often found in perivascular areas or show perivascular
accentuation when inﬁltrating the tumor tissue. In addition,
TILs may be observed in the invasive edge of the tumor, an
area much larger and less deﬁnable than the invasive mar-
gin of epithelial tumors. Immunohistochemical studies in
gliomas have identiﬁed microglia/macrophages and various
lymphocyte subsets including CD8+, CD4+, FOXP3+,
and CD45R0+ lymphocytes among others.326–328 Rutledge
et al327 used a simple H&E-based 3-tiered scoring system to
assess TILs in glioblastomas and identiﬁed signiﬁcant
associations with the sarcomatous, gemistocytic, epi-
thelioid, and giant cell histologic subtypes, which cluster
within the mesenchymal molecular class. A number of
studies have addressed the prognostic role of TILs in glio-
mas, however, the strength of these studies is generally
limited by sample size issues, retrospective design, and
nonstandardized assessment of lymphocytic inﬁltration. As
a result the studies are inconsistent with some showing a
prognostic role of certain TIL subsets and others showing
no association with patient outcome (reviewed by Bien-
kowski et al324). Adequately designed studies investigating
a predictive role of TILs for response to immunotherapies
in gliomas are not yet available.
As the methodology of TIL assessment in gliomas
varies between studies no clear recommendations on pre-
ferred assessment algorithms can be made. Visualization of
TIL subsets may require immunohistochemical staining for
speciﬁc immune cell markers to facilitate clear separation
from other cell types of the glioma microenvironment, such
as preexisting or neoplastic small astrocytic or oligoden-
droglial cells. However, there are no systematic studies
investigating the optimal method of TIL enumeration or
classiﬁcation and there is great variability in the techniques
used in published studies, including estimation of TIL
content by visual impression, manual counting, and
computer-assisted evaluation. Another area of uncertainty
is the tumor compartment in which TILs should be assessed
as areas of interest include perivascular spaces, intra-
tumoral areas, perinecrotic areas, the invasive edge, and,
where present, the tumor stroma compartment.
The exact role of immune cells in glioma and their
potential as clinically relevant biomarkers informing
patient management and treatment decisions also remains
unclear. Currently, many immunotherapeutic clinical trials
enrolling glioma patients are ongoing and investigation of
immune cell inﬁltration as prognostic or predictive markers
should be systematically analyzed in translational com-
panion projects of these studies. An important issue that
needs to be addressed in this context is the deﬁnition of
standardized assessment algorithms of TIL inﬁltrates for
gliomas. Given the speciﬁc architecture and histomorphol-
ogy of gliomas, our proposed guidelines for other tumor
types such as carcinomas may not be directly applicable to
these tumors.
Meningiomas
Lymphocyte inﬁltration of variable extent is com-
monly found in meningiomas. In most cases TILs are
not very prominent, but rare cases display striking amounts
of intratumoral immune cells, for example, the
lymphoplasmacyte-rich meningioma subtype.329 Some
studies have reported higher TIL amounts in atypical and
malignant meningiomas as compared with benign menin-
giomas, while other studies have observed lower TIL
numbers with higher meningioma grade.324,325,330 TILs in
meningiomas can be present in the perivascular area or
intratumorally, and may include CD8+, CD4+, CD45+,
and CD20+ lymphocytes, natural killer cells, and others.
The biological and clinical signiﬁcance of TILs in menin-
gioma is unclear and further study is required. Of note,
immunotherapy with immune checkpoint inhibitors of
the PD-1/PD-L1 axis has been suggested as a potential
therapeutic option in recurrent meningioma, and TIL
inﬁltration may be a candidate biomarker that should be
investigated in such studies.331 However, as for gliomas,
the methodology of TIL assessment is nonstandardized and
needs to be elaborated in systematic investigations.
DISCUSSION
In this review, we have focused on common solid
tumors in which data about the potential signiﬁcance of
TILs is available or emerging. The importance of TILs
and host-tumor immune interactions is clearly not limited
to these tumor types, and further exploration of less
common or less well-studied tumors such as cervical
carcinoma, sarcomas, and pediatric malignancies is
anticipated with interest. As can be seen from the above
discussion, approaches to TIL scoring have varied both
between and within tumor types. Through the eﬀorts of
researchers, clinicians and pathologists, the signiﬁcance of
TILs is gaining increasing recognition. However, a
standardized methodology would help to increase the
quantity and quality of comparable evidence and enable
the implementation of TIL scoring in large-scale clinical
trials and routine histopathologic practice. The consensus
methodology we propose has limitations and many open
questions remain, as discussed in part 1 of this review.
These methods should be considered a tool for further
research, to investigate both the signiﬁcance of TILs in
solid tumors and how we can best assess and describe the
host immune response to tumors. They can be used as a
reference against which other methods can be tested,
and should be thoroughly validated for reproducibility
and utility. Signiﬁcant results have already been demon-
strated using this methodology in diverse tumor types
including gastric cancer, lung cancer and laryngeal squ-
amous cell carcinoma. However, these recommendations
may not be translatable into other tumor types, such as
gliomas, for which further work is required to develop a
standardized, reproducible and valid methodology. As
more evidence becomes available, recommendations will
be reviewed, expanded and clariﬁed. It is hoped this
proposed standardized methodology will help clinicians,
researchers and pathologists to evaluate the utility of TILs
assessment with a view to both prognosis and prediction
of response to treatment.
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